GLP-1 agonists

PreclinicalSmall molecule

GLP-1 agonists is one of 8 small molecule programs targeting Magnetic Resonance Imaging. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Magnetic Resonance ImagingCompleted

Magnetic Resonance ImagingPreclinical

Completed

Competition

Competitive Landscape

9 competitors in Magnetic Resonance Imaging

#DrugCompanyPhaseTrials

Elucirem

GGuerbet

Approved

1 2

Minipress

Pfizer

Phase 2

2 3

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 1

1 4

D-Cycloserine

MMassachusetts General Hospital

Preclinical

1 5

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

PSMA-11

NNational Cancer Institute (NCI)

Preclinical

1 7

PSMA-1007

AABX advanced biochemical compounds GmbH

Preclinical

1 8

GLP-1 agonists

MMedical College of Wisconsin

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedRecruiting

Psoriatic Arthritis (psa)

NCT07111494

Clinical

Trials by Indication[1]

Magnetic Resonance Imaging1 trial

Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging

Completed·—·N/A·NCT03498001·42 enrolled

Psoriatic Arthritis (PsA)1 trial

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

Recruiting·MMedical College of Wisconsin·Approved·NCT07111494·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GLP-1 agonists. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 agonists compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1 agonists. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical College of Wisconsin

GLP-1 agonists

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Magnetic Resonance Imaging1 trial

Psoriatic Arthritis (PsA)1 trial

References

Drug Info

Quick Facts

Related News